Detection and typing of human papillomavirus in cervical carcinomas in Russian women: a prognostic study

• Published in: Cancer 1999-05, Vol.85 (9), p.2011-2016
• Main Authors: van Muyden, R C, ter Harmsel, B W, Smedts, F M, Hermans, J, Kuijpers, J C, Raikhlin, N T, Petrov, S, Lebedev, A, Ramaekers, F C, Trimbos, J B, Kleter, B, Quint, W G
• Format: Article
• Language: English
• Subjects: Adult; Age Distribution; Female; Genotype; Humans; Immunohistochemistry; Lymphatic Metastasis; Neoplasm Staging; Papillomaviridae - genetics; Papillomaviridae - isolation & purification; Polymerase Chain Reaction; Retrospective Studies; Russia; Survival Rate; Uterine Cervical Neoplasms - mortality; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - virology
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/(SICI)1097-0142(19990501)85:9<2011::AID-CNCR19>3.0.CO;2-N

The correlation between human papillomavirus (HPV) infection and tumor prognosis in 159 Russian women with cervical carcinoma was investigated. The presence of various HPV types was correlated with the histologic parameters of the carcinomas and with their immunoreactivity with antibodies to p53, Ki-67-Ag, and bcl-2. Formalin fixed, paraffin embedded tissue specimens representing 159 cases of International Federation of Gynecology and Obstetrics Stage I and II were used. HPV DNA was detected by polymerase chain reaction (PCR) using a general primer set that targets the L1 region and synthesizes a product of only 65 base pairs. The HPV types were determined by direct sequencing and compared with known HPV types. All 159 carcinomas were positive for HPV. HPV 16 (64.8%) was most frequently found, followed by HPV 18 (10.7%) and HPV 45 (8.2%). In 6 patients (3.8%), HPV types could not been further classified, and these cases were therefore categorized as HPV X. Although a trend was noted toward poorer prognosis for women with carcinomas harboring HPV types 16, 18, and 45 than for patients with carcinomas harboring HPV types 31, 33, 35, 52, 56, 58, and 68, the differences were not statistically significant. The prevalence of adenocarcinoma and adenosquamous carcinoma was higher among HPV 18 positive patients than among patients with the other known HPV types (P=0.0002). The rate of HPV positivity in these 159 cervical carcinomas was 100%. These findings challenge the assumption that HPV negative cervical carcinomas exist. This high rate might be attributed to the use of a new broad-spectrum HPV PCR test. HPV typing in cervical carcinoma was not significantly related to clinical outcome. HPV 18 was significantly more frequently found in adenocarcinoma and adenosquamous carcinoma. The possibility of classifying HPV 45 as an oncogenic high risk type should be considered.